• E-mail :[email]
  • Phone : 01.53.98.79.80
  • Location : Paris, France
Last update 2016-10-18 13:44:09.905

Angélique Levoye Associate Professor

Course and current status

Sept 2016 : Associate Professor, INSERM U970  « Regenerative Therapies For Cardiac And Vascular Diseases » - Paris Cardiovascular Research Center (PARCC) 

2011-2016: Associate Professor, « INSERM-University Chair position » INSERM U1148  « Laboratory of Vascular Translational Science» - Paris 13 University

 2010-11 : Research assistant in F. Arenzana-Seisdedos ’s laboratory at the Pasteur Institute, Paris, France

2006-09 : Post-doctoral fellow in F. Bachelerie‘s team at the Pasteur Institute, Paris, France

2002-05 : PhD in molecular pharmacology in R. Jockers ’s team at the Cochin Institute, Paris, France (Paris 11 University)

• 2001-02 : Master degree in cell biology at the Lille 1 University, France

Scientific summary

I received my PhD in Biochemistry and Molecular Biology from Paris Sud 11 University in 2005. During my PhD in Ralf Jocker’s Team at Cochin Institute in Paris, my work consisted to investigating the functional consequences of melatonin receptors heterodimerization and to searching the function of orphan G-Protein Coupled Receptor (GPCR) GPR50. We showed that GPR50 antagonize the MT1 melatonin receptor function through heterodimerization. This work was the first demonstration that orphan GPCR can modulate the function of GPCR with identified ligand and known function. This study led to new concept based on the existence of ligand-independent functions for orphan GPCRs through heterodimerization.

Then, I jointed, in February 2006, the Françoise Bachelerie’s Team at Pasteur Institute in Paris as post-doctoral fellow. During this period, I’m interested to the interactions between the chemokine CXCL12/SDF-1 and it’s receptors CXCR4 and CXCR7 in a physiological and pathological context. My project consisted to exploring the physiopathology of the WHIM syndrome, a rare and inherited chemotactic disorder determined by a pathologic gain of function of CXCR4 in response to CXCL12. I found that CXCR4 desensitization is selectively regulated by GRK3 and the dysregulation of which in two WHIM patients leads to the enhanced CXCR4 functioning. I have also investigated the contribution of CXCR7, the second receptor of CXCL12 in biological activities of this chemokine. I showed that CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. During, my PhD and my post-doctoral training I have acquired a variety of technical skills ranging from cell biology, biochemistry and BRET Technology. I also contributed to the development of fluorescence binding and internalization assays (Tag-Lite assay) for chemokine receptors in collaboration with CisBio Bioassays, a company working with GPCRs and Homogenous Time-Resolved Fluorescence (HTRF) technology.

Since 2011, I have a permanent position as associate professor at the Paris 13 University. I worked at INSERM U1148 (Laboratory of Vascular Translational Science) at Bichat hospital in Paris where I investigated the role of High Density Lipids (HDL) receptors ; SR-B1 and Sphingosine-1-Phosphate (S1P) receptors family in vasculo-protective effects of HDL on Blood-Brain Barrier in ischemic sroke.

Actually, I joint, the Jean-Sebastien Silvestre ’s Team at PARCC in Paris, and I interested to the role of chemokine CXCL12 on post-infarctus cardiac remodeling. 

Image d’exemple